Labiotech.eu

News and Trends 8 Dec 2015

Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials

Threshold Pharmaceuticals in the US has failed at getting its hypoxia prodrug evofosfamide through phase III trials for two types of cancer, and as a result has lost Merck’s partnership on the program. Evofosfamide (TH-302) is an investigational hypoxia-activated prodrug discovered by Threshold Pharmaceuticals in Pennsylvania (US). The prodrug is activated only at very low […]

December 8, 2015 - 2 minutesmins - By Dani Bancroft

morphosys multiple myeloma immunooncology mor202

News and Trends 7 Dec 2015

Best-in-Class Label for Blood Cancer Trial by Billion Euro Biotech

Latest results of MorphoSys candidate for Multiple Myeloma show that it was Celgene’s loss when it abandoned the phase I/IIa trial partnership on blood cancer. Announced at the American Society of Hematology (ASH) Annual Meeting this weekend in Orlando (US), the phase I/IIa drug for blood cancer from MorphoSys has shown good tolerability for this […]

December 7, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 7 Dec 2015

Hydra’s Immortality is not Myth: Polyps Genetically Reprogram Skin Cells into Neurons

Relatives of the Jellyfish, researchers at the University of Geneva (Switzerland) have now proven the regenerative abilities of Hydra involved reprogramming cells. Does this have any implications for Neurodegenerative disease? Remember the Greek myth of Hydra? Amongst other twelve labours, Hercules had to slay the nine-headed monster Hydra which, in case nine jaws weren’t enough, […]

December 7, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 5 Dec 2015

What Happened this week? Cellectis’ CEO, Rare Disease, CRISPR

Monday: Cellectis CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer” Tuesday: Rare Diseases: Still a ‘Blue Ocean’ for Biotechs? Wednesday: Crops Successfully Edited with CRISPR have no Transgenes! Is this Still GMO? Thursday: History of Biotech: How the “First” Biotech Patent Generated Millions Friday: Black Friday Ruin as TWO […]

December 5, 2015 - 1 minutemin - By Philip Hemme

cytotools medday stock black friday drop phase III fail

News and Trends 4 Dec 2015

Black Friday Ruin as TWO Biotechs Fail in Phase III Trials

A shocking Black Friday for these two Biotechs: Both CytoTools (Germany) and MedDay (France) phase III trials in chronic disease flopped massively, and stocks dropped as much as 85% in one day… Multiple Sclerosis Headliner, MedDay’s MD1003, has flopped in its phase III trial after failing to meet its primary endpoint. This is a disastrous […]

December 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Dec 2015

Dutch Seed-Enhancer Acquired for €155M by UK Chemical Giant

Croda International is reinforcing its agri-business department with the €155M-acquisition of Incotec. The chemical producer expanded this way its biological portfolio making a move into the market for additives to improve the performance of crop seeds. This British chemical manufacturer is the world’s second-largest maker of cosmetic ingredients, although its business is not restricted to […]

December 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Dec 2015

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

This week we leave the old city of Oxford and travel South East across the channel, through France and arrive at our destination, Zurich, Switzerland. This wonderful city is famous for its many churches (including the Minster), the largest church clock in Europe, found on St Peter’s and is the home of many celebrities including […]

December 4, 2015 - 2 minutesmins - By Philip Hemme

bioplastics carbios bioon france pet green

News and Trends 3 Dec 2015

Bioplastics Breakthrough: French Cleantech Now Able to Infinitely Recycle PETs!

French Carbios have now managed to adapt their enzymatic bioplastics manufacturing process to make Green PET (polyethylene terephthalate) from the petrochemical PET – one of the most common plastics. Whilst various green initiatives push for better regulation of recycling (a prime example being in Berlin!), in reality only around 10% of plastic collected is actually […]

December 3, 2015 - 3 minutesmins - By Dani Bancroft

cohen boyer patents standford gene editing technology biotech

News and Trends 3 Dec 2015

History of Biotech: How the “First” Biotech Patent Generated Millions

The Cohen-Boyer patents were now issued 35 years ago at Stanford University… so what were they and how did they shape the Modern Biotechnology Field? Recombinant DNA (rDNA) products provided a new technology platform for a range of industries, resulting in over US$35 billion in sales for an estimated 2,442 new products. After Genentech was […]

December 3, 2015 - 5 minutesmins - By Marie Godar

News and Trends 3 Dec 2015

Meet the Company Fighting Autoimmune Diseases with a Novel Immunotherapy

BIO-Europe 2015 was a good opportunity for us to meet people who are playing a key role in the Biotech industry. I had the opportunity to meet Miguel Sieler, CEO of Neovacs, a company that can potentially be the first to develop a therapeutic vaccine for lupus patients! Neovacs is a French biotechnology company developing […]

December 3, 2015 - 4 minutesmins - By Joachim Eeckhout

sainsbury john innes centre brassica laboratory crispr

News and Trends 2 Dec 2015

Crops Successfully Edited with CRISPR have no Transgenes! Is this Still GMO?

The CRISPR/Cas9 gene-editing tool is allowing rapid scientific advances in many fields, including human health. Now it has been shown that crop research can also benefit the fight for improved Food Security. Research at the John Innes Centre and the Sainsbury Lab (UK) have successfully edited crops so that future generations of these veggies have […]

December 2, 2015 - 3 minutesmins - By Dani Bancroft

kesios myeloma imperial innovations london

News and Trends 2 Dec 2015

An Imperial College Based Start-Up Has Raised €27M in Series A for a Blood Cancer Drug

Kesios is a start-up Biotech based in London (UK) which has raised over €27M in a Series A funding round for its pipeline targeting the fight against multiple myeloma. A syndicate of UK investors has jumped at the chance to fund this cancer-fighting biotech, whose nuclear factor kappa B (NF-κB)signal pathway targeting pipeline has promise […]

December 2, 2015 - 3 minutesmins - By Dani Bancroft

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials

Best-in-Class Label for Blood Cancer Trial by Billion Euro Biotech

Hydra’s Immortality is not Myth: Polyps Genetically Reprogram Skin Cells into Neurons

What Happened this week? Cellectis’ CEO, Rare Disease, CRISPR

Black Friday Ruin as TWO Biotechs Fail in Phase III Trials

Dutch Seed-Enhancer Acquired for €155M by UK Chemical Giant

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

Bioplastics Breakthrough: French Cleantech Now Able to Infinitely Recycle PETs!

History of Biotech: How the “First” Biotech Patent Generated Millions

Meet the Company Fighting Autoimmune Diseases with a Novel Immunotherapy

Crops Successfully Edited with CRISPR have no Transgenes! Is this Still GMO?

An Imperial College Based Start-Up Has Raised €27M in Series A for a Blood Cancer Drug

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!